WC
DMAC icon

Wexford Capital’s DiaMedica Therapeutics DMAC Stock Holding History

Wexford Capital’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-88,860
Closed -$184K – 128
2019
Q3 		$184K Sell
88,860
-311,140
-78% -$1.01M 0.03% 107
2019
Q2 		$1.98M Sell
400,000
-75,000
-16% -$259K 0.23% 66
2019
Q1 		$2.16M Hold
475,000
– – 0.18% 50
2018
Q4 		$1.38M Buy
+475,000
New +$1.49M 0.12% 46

Other funds holding DMAC

MHP
Manatuck Hill Partners Westport, Connecticut $370M AUM 95.53% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return

Wexford Capital's DMAC Position: Q4 2019 in Review

Wexford Capital sold out of DiaMedica Therapeutics (DMAC) in Q4 2019, closing a stake of 88,860 shares — an estimated $184K sold.

Wexford Capital first reported a position in DMAC in Q4 2018 and held it in 4 quarters. The position peaked at $2.16M in Q1 2019. 15 funds tracked by Wall St. Rank hold DMAC as of Q4 2019.

  • Wexford Capital reported no remaining DiaMedica Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Wexford Capital sold 88,860 DiaMedica Therapeutics shares in Q4 2019, an estimated $184K.
  • Wexford Capital first reported a position in DiaMedica Therapeutics in Q4 2018 and held it in 4 quarters.
  • Wexford Capital's DiaMedica Therapeutics position peaked at $2.16M in Q1 2019.
  • 15 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q4 2019.

Based on Wexford Capital's 13F filing for Q4 2019, filed 14 Feb 2020.